Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0093 | 0.2407 | 0.2407 |
Loa Loa (eye worm) | hypothetical protein | 0.0151 | 1 | 1 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0151 | 1 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0151 | 1 | 0.5 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0151 | 1 | 0.5 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0151 | 1 | 0.5 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0075 | 0 | 0.5 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0134 | 0.7743 | 0.5 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0151 | 1 | 1 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0076 | 0.0151 | 0.0151 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0151 | 1 | 1 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0151 | 1 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0151 | 1 | 0.5 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0151 | 1 | 1 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0151 | 1 | 0.5 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0151 | 1 | 0.5 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0151 | 1 | 1 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0151 | 1 | 1 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0151 | 1 | 1 |
Trypanosoma cruzi | p450 reductase, putative | 0.0151 | 1 | 0.5 |
Brugia malayi | FAD binding domain containing protein | 0.0151 | 1 | 1 |
Leishmania major | p450 reductase, putative | 0.0151 | 1 | 1 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0151 | 1 | 0.5 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0075 | 0 | 0.5 |
Chlamydia trachomatis | sulfite reductase | 0.0093 | 0.2407 | 0.5 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0151 | 1 | 1 |
Giardia lamblia | Hypothetical protein | 0.0134 | 0.7743 | 0.5 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0151 | 1 | 0.5 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0151 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Analgesic activity (functional) | = 75.21 % | Analgesic activity of the compound in mice | ChEMBL. | 1560442 |
Analgesic activity (functional) | = 75.21000000000001 % | Analgesic activity of the compound in mice | ChEMBL. | 1560442 |
Inhibition (functional) | = 8 % | The compound was evaluated for inhibition of edema induced by histamine at 10 mg/mL | ChEMBL. | 1560442 |
Inhibition (functional) | = 8 % | The compound was evaluated for inhibition of edema induced by histamine at 10 mg/mL | ChEMBL. | 1560442 |
Inhibition (functional) | = 10 % | The compound was evaluated for inhibition of edema induced by bradykinin at 100 ug/mL | ChEMBL. | 1560442 |
Inhibition (functional) | = 10 % | The compound was evaluated for inhibition of edema induced by bradykinin at 100 ug/mL | ChEMBL. | 1560442 |
Inhibition (functional) | = 15 % | The compound was evaluated for inhibition of edema induced by serotonin at 250 ug/mL | ChEMBL. | 1560442 |
Inhibition (functional) | = 15 % | The compound was evaluated for inhibition of edema induced by serotonin at 250 ug/mL | ChEMBL. | 1560442 |
Inhibition (functional) | = 25.9 % | Inhibitory activity of the compound was tested against carrageenan induced paw edema in mice | ChEMBL. | 1560442 |
Inhibition (functional) | = 25.9 % | Inhibitory activity of the compound was tested against carrageenan induced paw edema in mice | ChEMBL. | 1560442 |
Inhibition (functional) | = 32 % | The compound was evaluated for inhibition of edema induced by arachidonic acid at 1 mg/mL | ChEMBL. | 1560442 |
Inhibition (functional) | = 32 % | The compound was evaluated for inhibition of edema induced by arachidonic acid at 1 mg/mL | ChEMBL. | 1560442 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.